R&D key to developing HIV prevention options
"We are at a crucial point in the history of the AIDS response. Sustained investment in research has led to major scientific advances in the past few years," Luiz Loures, deputy executive director for the United Nations HIV/AIDS program, said. "Now we need to fast-track implementation and ensure that results are made available to people at scale and with urgency."
In the past 10 years, there have been more investments in the research and development industry to further advanced HIV prevention.
"Ending AIDS once and for all will require critical investments in prevention research and development," IAVI CEO Margie McGlynn said. "This report highlights funders whose commitment should be celebrated, but also underscores the need for public-sector and philanthropic stakeholders to re-engage to the benefit of individuals, communities and economies worldwide. The links between improvements in health and sustainable development are clear."
Significant funding has gone to applying research for existing prevention options, as reported by the HIV Vaccines and Microbicides Resources Tracking Working Group.
"Innovative science needs innovative funding,” Mitchell Warren, AVAC executive director, said. “We need an expanded and more diverse global cadre of funders who will be involved in and dedicated to advancing HIV prevention R&D and ensuring that new options like PrEP do not sit on the shelf unused because we don't know how to effectively deliver them.”